共 50 条
Impact of text reminders on pneumatic compression device (PCD) compliance in patients with breast cancer-related lymphedema
被引:0
|作者:
Maingi, Shail
[1
,2
]
O'Malley, Ellen M.
[3
]
机构:
[1] St Peters Hlth Partners, Albany, NY 12208 USA
[2] Dana Farber Canc Inst, 101 Columbian St, South Weymouth, MA 02190 USA
[3] OMalley Med Commun, Victoria, MN 55386 USA
关键词:
Breast cancer-related lymphedema;
Pneumatic compression device;
Quality of life measures;
Treatment compliance;
ADHERENCE;
WOMEN;
LIMB;
D O I:
10.1007/s00520-023-08246-9
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
PurposeDo cell phone text reminders impact the rate of compliance with pneumatic compression device (PCD) therapy among women with breast cancer-related lymphedema (BCRL)?MethodsA prospective, randomized, 2-group feasibility study conducted at 2 centers. Participants were adult females (>= 18 years old) with unilateral BCRL who had the capability of receiving reminder text messages. All participants underwent PCD therapy. Participants were randomized 1:1 to control (no text messages) or test group (received text message reminders if the PCD had not been used for 2 consecutive days). The rate of compliance between treatment groups was the main outcome measure. Secondary outcome measures were changes in arm girth, quality of life (QOL), and symptom severity.ResultsTwenty-nine participants were enrolled and randomized, 25 were available for follow-up at 60 days (14 test, 11 control). Overall, 52.2% (12/23) of all participants were completely compliant, an additional 43.5% (10/23) were partially compliant, and 1 patient (4.3%) was noncompliant. The test and control groups did not differ in device compliance. In the pooled population, weight, BMI, and arm girth were improved. Overall disease-specific QOL and symptom severity were improved. Regression analysis showed benefits were greater among participants with higher rates of compliance.ConclusionsAutomated text reminders did not improve compliance in patients with BCRL as compliance rates were already high in this patient population. Improvements in weight, BMI, arm girth, disease-specific quality of life, and symptom severity measures were observed regardless of the treatment assignment. Full compliance resulted in greater functional and QOL benefits.Trial registrationThe study was registered at www.clinicaltrials.gov (NCT04432727) on June 16, 2020.
引用
收藏
页数:8
相关论文